Claims
- 1. A recombinant papilloma virus like particle (VLP) for introduction of a peptide into cells, comprising a major capsid protein L1 of human papilloma virus (HPV-L1 protein) wherein the major capsid protein L1 of human papilloma virus has been intentionally modified by substitution of specific amino acids to abolish major type specific epitopes causing production of neutralising antibodies.
- 2. The recombinant papilloma virus like particle (VLP) according to claim 1, wherein the L1 protein is derived from human papilloma virus 16.
- 3. The recombinant papilloma virus like particle (VLP) according to claim 2, wherein the L1 protein of HPV 16 has been modified by substitution of two or more of amino acids selected from the group consisting of Asn56, Asp138, Asn270, Asn285, Ile348, Ser349, Thr350, Ser351, Glu352, THr353.
- 4. The recombinant papilloma virus like particle (VLP) according to claim 1, wherein the peptide is genetically fused to the L1 protein.
- 5. A composition comprising the recombinant papilloma virus like particle (VLP) of claim 1.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9903534-7 |
Sep 1999 |
SE |
|
Parent Case Info
[0001] This application is a continuation-in-part under 37 C.F.R. § 1.53(b) of U.S. patent application Ser. No. 10/048,016, filed on Jan. 28, 2002, for Vaccine, which was a national stage filing under 37 C.F.R. § 371 of International Application No. PCT/SE00/01808, filed on Sep. 19, 2000.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10048016 |
Jan 2002 |
US |
Child |
10759125 |
Jan 2004 |
US |